AstraZeneca Canada Inc., v. Apotex Inc., (SCC #36654) — leave to intervene granted

The Supreme Court has granted leave to intervene to the following: Innovative Medicines Canada and BIOTECanada (jointly); the Centre for Intellectual Property Policy; the Canadian Generic Pharmaceutical Association; the Fédération internationale des conseils en propriété intellectuelle; the Intellectual Property Owners Association and the Intellectual Property Institute of Canada.

The Supreme Court had previously granted AstraZeneca leave to appeal in its application, which asks the correct applicable standard for patent utility in Canada and whether a promised utility doctrine properly exists, see our summary here.